Compare 8x8 Inc (EGHT) vs GE HealthCare Technologies Inc. Common Stock (GEHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs GE HealthCare Technologies Inc. Common Stock — how do they compare? 8x8 Inc trades at $2.02 (market cap $296.09M), while GE HealthCare Technologies Inc. Common Stock trades at $68.62 (market cap $31.07B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 104.9× 8x8 Inc's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals.
| EGHT | GEHC | |
|---|---|---|
Market Cap | $296.09M | $31.07B |
Volume | 1,073,599 | 3,443,020 |
Sector | Technology | Health |
52-Week High | $2.76 | $88.16 |
52-Week Low | $1.59 | $59.48 |
Typical Hold Time | 16 Days | — |
Enterprise Value | $563.02M | $39.53B |
Dividend Yield | — | 0.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.05, up 0.49% today, with a mixed technical picture showing bullish oscillators but bearish moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and projected profitability in 2026. Recent news highlights cost-saving customer implementations and AI platform growth, while analyst consensus remains divided with a $19.77 price target representing significant upside potential from current levels.
The stock presents a high-risk, high-reward opportunity with substantial upside if the company achieves projected profitability, though current negative earnings and high debt levels pose execution risks. Institutional interest is growing with recent position increases, but the stock requires careful monitoring of Q3 2026 earnings results and debt management progress.
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →
